Search Results for: biotechnolog

OncoArendi Therapeutics to Begin the Phase 1 Clinical Evaluation of its Novel Class of Medicines

Healthy volunteers study initiated for OATD-01, an innovative therapy for the treatment of asthma Warsaw, Poland, October 9, 2017 - OncoArendi Therapeutics announced today that this week the Company will initiate a Phase 1 study designed

Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o.

On January 15, 2015 Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o. via the IPOPEMA 112 FIZAN fund. OncoArendi is a dynamically growing biotechnological company, which develops innovative anti-inflammatory and antitumor drugs with unique mechanisms of